Phio Pharmaceuticals(US:PHIO)2025-11-13 21:20Financial Performance - Phio Pharmaceuticals reported a net loss of $2.4 million for Q3 2025, compared to a net loss of $1.5 million in Q3 2024, reflecting an increase in operating expenses[12]. - Total operating expenses for Q3 2025 were $2.5 million, compared to $1.6 million in Q3 2024[20]. Research and Development - Research and development expenses increased to $1.2 million in Q3 2025 from $0.6 million in Q3 2024, primarily due to higher clinical trial costs[10]. - In the ongoing Phase 1b trial of PH-762, 100% tumor clearance was achieved in one patient, with over 90% clearance in another and over 50% in a third patient[2]. - A total of 18 patients have completed treatment in the Phase 1b trial, with 6 achieving complete response and 2 achieving near complete response[3]. - The company has no reported dose-limiting toxicities or clinically relevant adverse effects in patients receiving PH-762[4]. Cash and Assets - As of September 30, 2025, the company had cash and cash equivalents of approximately $10.7 million, up from $5.4 million at December 31, 2024[9]. - The company’s total assets increased to $11.5 million as of September 30, 2025, compared to $5.7 million at December 31, 2024[22]. Future Financing - The company expects to raise approximately $12.1 million from warrant inducement financing, extending its cash runway into the first half of 2027[8]. Operating Expenses - General and administrative expenses rose to $1.3 million in Q3 2025, up from $0.9 million in Q3 2024, driven by increased professional fees and employee stock compensation[11].